Research Focus: Targeting the MCL-1 Pathway With CDK9 Inhibitors in AML

In this slideset and commentary, I explore the novel approach of inhibiting CDK9 as a way of downregulating MCL-1 and thereby minimizing survival signals in AML cells.

Eunice S. Wang, MD

Certified Slideset

In this CME-certified slideset, CCO’s expert faculty describes the rationale for targeting MCL-1 with CDK9 inhibitors in AML and discusses preclinical studies and early clinical trials of investigational CDK9 inhibitors.

Eunice S. Wang, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: May 3, 2019 Expired: May 2, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Boston Biomedical, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?